SecurAcath

SecurAcath is a medical device brand and the flagship product of Interrad Medical, Inc., a medical device company based in Plymouth, Minnesota, in the United States. The product is a subcutaneous catheter securement system designed to hold percutaneous catheters — such as peripherally inserted central catheters (PICCs) and other central venous catheters — securely in place without the use of sutures or adhesives. Instead of relying on surface adhesive dressings or stitches, SecurAcath uses small, flexible feet placed just beneath the skin at the insertion site, a design the company markets under the tagline "Just One, For the Life of the Line." The device is intended to remain in place for the life of the catheter, reducing the need for re-securement and eliminating needle sticks associated with suturing. The brand positions itself around clinical evidence and health-economic value. According to the official website, SecurAcath has been evaluated in six comparative studies across five countries involving 12,815 patients, spanning neonates to geriatrics and covering over 1.5 million catheter days. The company cites pooled data from publications by Hawes (2023), McParlan (2020), Dolcino (2017), Kleidon (2024), Goossens (2018), and Pittiruti (2022). A separate analysis by UAMS of 7,779 patients over four years of Central Line Associated Bloodstream Infection (CLABSI) data, published by Rowe et al. in the American Journal of Infection Control (2020), reported a substantial difference in relative risk of CLABSI between PICCs secured with SecurAcath and those secured with an adhesive device, with a consistent reduction observed over four years. The brand also highlights the SECURED superiority randomized clinical trial, which examined securement to prevent non-cuffed central venous catheter dislodgement in pediatrics. Lead author Tricia Kleidon, RN, MNursePrac, is quoted on the website saying that catheter dislodgement is a major clinical problem for pediatric patients with potentially life-threatening consequences, and that the study results clearly show SecurAcath reduces dislodgement and saves money, supporting preferential use over adhesive device securement. SecurAcath has also received an Innovative Technology Contract from Vizient, described by the company as the largest member-driven healthcare performance improvement company. Interrad Medical describes itself as committed to the development and commercialization of innovative medical devices for use in minimally invasive interventional and surgical procedures. The company states that SecurAcath is its first product and that the device is experiencing rapid growth globally. The brand therefore sits at the intersection of vascular access, infection prevention, and catheter securement, sold to hospitals and clinicians rather than directly to consumers.

Interrad Medical, Inc. is a medical device company located in Plymouth, Minnesota, in the United States. The company states that its first product is the SecurAcath Subcutaneous Catheter Securement System, described as a simple yet revolutionary device that can hold percutaneous catheters securely in place without sutures or adhesives. Interrad Medical frames its mission as being committed to the development and commercialization of innovative medical devices for use in minimally invasive interventional and surgical procedures. SecurAcath was developed to address a persistent problem in vascular access: keeping central venous catheters and PICCs reliably in place over the life of the line. Traditional securement methods rely on adhesive devices or sutures, which can fail, cause skin irritation, or require additional punctures. SecurAcath instead uses small, flexible feet placed just beneath the skin at the insertion site, a mechanism the company summarizes with the phrase "Just One, For the Life of the Line." The design requires no adhesives for securement and no sutures or additional punctures, which the company says eliminates needle sticks, improves efficiency, and lowers the total cost of patient care. As the product matured, Interrad Medical built a clinical evidence base around it. The official website states that SecurAcath has been studied in six comparative studies across five countries, covering 12,815 patients from neonates to geriatrics and more than 1.5 million catheter days, with data pooled from publications by Hawes (2023), McParlan (2020), Dolcino (2017), Kleidon (2024), Goossens (2018), and Pittiruti (2022). A separate analysis by UAMS examined 7,779 patients over four years of Central Line Associated Bloodstream Infection (CLABSI) data, comparing outcomes of PICCs secured with SecurAcath versus an adhesive device and finding a substantial difference in relative risk of CLABSI among securement devices, with a consistent reduction observed over four years; this work was published by Rowe et al. in the American Journal of Infection Control (2020), Vol. 48, Dec. The brand has also been evaluated in the SECURED superiority randomized clinical trial, which studied securement to prevent non-cuffed central venous catheter dislodgement in pediatrics. According to the website, lead author Tricia Kleidon, RN, MNursePrac, said that catheter dislodgement is a major clinical problem for pediatric patients with potentially life-threatening consequences, and that the results clearly show SecurAcath reduces dislodgement and saves money, supporting preferential use over adhesive device securement. In addition, SecurAcath was awarded an Innovative Technology Contract from Vizient, described as the largest member-driven healthcare performance improvement company. Interrad Medical states that the SecurAcath device is now experiencing rapid growth globally. The company's board has included David Kaysen as Chairman, who has more than 25 years of executive management and board experience in the medical products and services industry, and Martin Walton, who joined the Excalibur Group London in early 2011 after a 25-year career in the capital markets. The brand remains active and is marketed to hospitals and clinicians internationally.

• Interrad Medical, Inc. founded in Plymouth, Minnesota (exact year not stated in evidence).

• SecurAcath Subcutaneous Catheter Securement System launched as Interrad Medical's first product.

• Rowe et al. publish UAMS analysis of 7,779 patients in the American Journal of Infection Control (Vol. 48, Dec 2020).

• SECURED superiority randomized clinical trial on pediatric catheter securement published.

• SecurAcath awarded an Innovative Technology Contract from Vizient.

Clinically evidenced, adhesive- and suture-free catheter securement that reduces dislodgement, CLABSI risk, and total cost of care.

• SecurAcath Subcutaneous Catheter Securement System

  A securement device using small, flexible feet placed just beneath the skin at the insertion site to hold percutaneous catheters in place without sutures or adhesives.

1. 1Home - SecurAcathsecuracath.com
2. 2About Interrad - SecurAcathsecuracath.com
3. 3SecurAcath (United States) - Wikidatawikidata.org